Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 21-Apr-23 5:08 PM View:  | Sensenig Bethany Chief Financial Officer | 9 Meters Biopharma, Inc. (NMTR) | 21-Apr-23 | Private Sale | 9,100 | $1.21 | $11,011.00 | (18%) 50.18K to 41.08K | |
| 31-Mar-23 4:01 PM View: | Ventimiglia Samantha Director | 9 Meters Biopharma, Inc. (NMTR) | 29-Mar-23 | Grant | 7,885 | -- | -- | 100% 0 to 7.88K | |
| 31-Mar-23 4:21 PM View: | Johnson Lorin K Director | 9 Meters Biopharma, Inc. (NMTR) | 29-Mar-23 | Grant | 7,885 | -- | -- | 186% 4.24K to 12.13K | |
| 31-Mar-23 4:35 PM View: | Sirgo Mark A Director | 9 Meters Biopharma, Inc. (NMTR) | 29-Mar-23 | Grant | 7,885 | -- | -- | 10% 79.1K to 86.98K | |
| 31-Mar-23 4:07 PM View: | Constantino Michael T. Director | 9 Meters Biopharma, Inc. (NMTR) | 29-Mar-23 | Grant | 7,885 | -- | -- | 261% 3.03K to 10.91K | |
| 31-Mar-23 4:28 PM View: | Rice Yehuda Michael Director | 9 Meters Biopharma, Inc. (NMTR) | 29-Mar-23 | Grant | 7,885 | -- | -- | 100% 0 to 7.88K | |
| 29-Mar-23 4:01 PM View: | Temperato John Chief Executive Officer Director | 9 Meters Biopharma, Inc. (NMTR) | 27-Mar-23 | Grant | 68,815 | -- | -- | 96% 71.38K to 140.19K | |
| 29-Mar-23 4:09 PM View: | Sensenig Bethany Chief Financial Officer | 9 Meters Biopharma, Inc. (NMTR) | 27-Mar-23 | Grant | 50,177 | -- | -- | 100% 0 to 50.18K | |
| 08-Jul-22 8:01 AM View: | Temperato John Chief Executive Officer Director | 9 Meters Biopharma, Inc. (NMTR) | 06-Jul-22 | Private Purchase | 125,000 | $0.23 | $28,462.50 | 10% 1.3M to 1.43M | |
| 06-Jul-22 4:43 PM View: | Sirgo Mark A Director | 9 Meters Biopharma, Inc. (NMTR) | 01-Jul-22 | Private Purchase | 175,000 | $0.25 | $42,962.50 | 13% 1.3M to 1.48M | |
| 24-May-22 4:01 PM View: | Constantino Michael T. Director | 9 Meters Biopharma, Inc. (NMTR) | 23-May-22 | Private Purchase | 16,000 | $0.48 | $7,608.00 | 36% 44.51K to 60.51K | |
| 19-May-22 4:01 PM View: | Sirgo Mark A Director | 9 Meters Biopharma, Inc. (NMTR) | 18-May-22 | Private Purchase | 106,383 | $0.47 | $50,000.00 | 8% 1.3M to 1.41M | |
| 19-May-22 4:09 PM View: | Temperato John Chief Executive Officer Director | 9 Meters Biopharma, Inc. (NMTR) | 18-May-22 | Private Purchase | 50,000 | $0.45 | $22,285.00 | 4% 1.25M to 1.3M | |
| 07-Mar-22 8:01 AM View: | Sirgo Mark A Director | 9 Meters Biopharma, Inc. (NMTR) | 03-Mar-22 | Private Purchase | 86,450 | $0.58 | $50,002.40 | 7% 1.21M to 1.3M | |
| 04-Mar-22 8:00 AM View: | Temperato John Chief Executive Officer Director | 9 Meters Biopharma, Inc. (NMTR) | 03-Mar-22 | Private Purchase | 100,000 | $0.56 | $55,590.00 | 9% 1.15M to 1.25M | |
| 03-Dec-21 7:34 AM View: | Sirgo Mark A Director | 9 Meters Biopharma, Inc. (NMTR) | 02-Dec-21 | Market Purchase | 50,000 | $0.89 | $44,500.00 | 4% 1.21M to 1.26M | 6% |
| 19-Nov-21 7:31 AM View: | Temperato John Chief Executive Officer Director | 9 Meters Biopharma, Inc. (NMTR) | 18-Nov-21 | Market Purchase | 50,000 | $1.05 | $52,500.00 | 5% 1.1M to 1.15M | |
| 22-Nov-21 7:30 AM View: | Sirgo Mark A Director | 9 Meters Biopharma, Inc. (NMTR) | 18-Nov-21 | Market Purchase | 20,000 | $1.06 | $21,200.00 | 2% 1.19M to 1.21M | |
| 15-Sep-21 8:12 AM View: | Sitar Edward J Chief Financial Officer | 9 Meters Biopharma, Inc. (NMTR) | 14-Sep-21 | Market Purchase | 15,000 | $1.22 | $18,300.00 | 8% 179.34K to 194.34K | (< 1%) |
| 08-Sep-21 8:15 AM View: | Sirgo Mark A Director | 9 Meters Biopharma, Inc. (NMTR) | 07-Sep-21 | Market Purchase | 73,529 | $1.36 | $99,999.40 | 7% 1.12M to 1.19M | (2%) |
| 26-Aug-21 8:18 AM View: | Constantino Michael T. Director | 9 Meters Biopharma, Inc. (NMTR) | 24-Aug-21 | Market Purchase | 18,000 | $1.14 | $20,520.00 | 53% 34.11K to 52.11K | 8% |
| 23-Aug-21 8:15 AM View: | Sirgo Mark A Director | 9 Meters Biopharma, Inc. (NMTR) | 20-Aug-21 | Market Purchase | 25,000 | $1.10 | $27,500.00 | 2% 1.1M to 1.12M | 0% |
| 19-Aug-21 8:16 AM View: | Temperato John Chief Executive Officer Director | 9 Meters Biopharma, Inc. (NMTR) | 18-Aug-21 | Market Purchase | 25,000 | $1.05 | $26,250.00 | 2% 1.08M to 1.1M | |
| 25-Jun-21 7:08 PM View: | Orbimed Israel Gp Ltd. 10% Owner | 9 Meters Biopharma, Inc. (NMTR) | 25-Jun-21 | Market Sale | 15,989,900 | $1.21 | $19,347,800.00 | (65%) 24.59M to 8.6M | |
| 25-Jun-21 7:08 PM View: | Orbimed Israel Gp Ltd. 10% Owner | 9 Meters Biopharma, Inc. (NMTR) | 24-Jun-21 | Market Sale | 319,255 | $1.38 | $440,572.00 | (1%) 24.91M to 24.59M | |
| 25-Jun-21 7:08 PM View: | Orbimed Israel Gp Ltd. 10% Owner | 9 Meters Biopharma, Inc. (NMTR) | 23-Jun-21 | Market Sale | 841,650 | $1.36 | $1,144,640.00 | (3%) 25.75M to 24.91M | |
| 13-May-21 6:34 PM View: | Orbimed Israel Gp Ltd. 10% Owner | 9 Meters Biopharma, Inc. (NMTR) | 11-May-21 | Exercise (in-the money or at-the-money) | 31,944 | $0.65 | $20,836.40 | < 1% 51.45M to 51.48M | |
| 06-Apr-21 4:16 PM View: | Temperato John Chief Executive Officer Director | 9 Meters Biopharma, Inc. (NMTR) | 05-Apr-21 | Private Purchase | 100,000 | $1.00 | $100,000.00 | 10% 977.52K to 1.08M | (11%) |
| 06-Apr-21 4:19 PM View: | Sirgo Mark A Director | 9 Meters Biopharma, Inc. (NMTR) | 05-Apr-21 | Private Purchase | 300,000 | $1.00 | $300,000.00 | 38% 795.55K to 1.1M | (11%) |
| 06-Apr-21 4:15 PM View: | Sitar Edward J Chief Financial Officer | 9 Meters Biopharma, Inc. (NMTR) | 05-Apr-21 | Private Purchase | 50,000 | $1.00 | $50,000.00 | 39% 129.34K to 179.34K | (11%) |
| 17-Dec-20 4:17 PM View: | Temperato John Chief Executive Officer Director | 9 Meters Biopharma, Inc. (NMTR) | 15-Dec-20 | Private Purchase | 153,846 | $0.65 | $99,999.90 | 19% 823.68K to 977.52K | |
| 17-Dec-20 4:17 PM View: | Sirgo Mark A Director | 9 Meters Biopharma, Inc. (NMTR) | 15-Dec-20 | Private Purchase | 230,769 | $0.65 | $150,000.00 | 41% 564.78K to 795.55K | |
| 17-Dec-20 4:17 PM View: | Sitar Edward J Chief Financial Officer | 9 Meters Biopharma, Inc. (NMTR) | 15-Dec-20 | Private Purchase | 61,538 | $0.65 | $39,999.70 | 91% 67.8K to 129.34K | |
| 01-Dec-20 4:10 PM View: | Temperato John Chief Executive Officer Director | 9 Meters Biopharma, Inc. (NMTR) | 27-Nov-20 | Grant | 203,667 | -- | -- | 33% 620.01K to 823.68K | |
| 03-Nov-20 4:14 PM View: | Orbimed Israel Gp Ltd. 10% Owner | 9 Meters Biopharma, Inc. (NMTR) | 30-Oct-20 | Acquisition (other) Duplicate | 1,943,730 | -- | -- | 8% 23.77M to 25.72M | |
| 03-Nov-20 4:14 PM View: | Darvish Nissim Director 10% Owner | 9 Meters Biopharma, Inc. (NMTR) | 30-Oct-20 | Acquisition (other) | 1,943,730 | -- | -- | 8% 23.77M to 25.72M | |
| 03-Nov-20 4:14 PM View: | Sirgo Mark A Director | 9 Meters Biopharma, Inc. (NMTR) | 30-Oct-20 | Acquisition (other) | 4,513 | -- | -- | < 1% 560.27K to 564.78K | |
| 03-Nov-20 4:13 PM View: | Temperato John Chief Executive Officer Director | 9 Meters Biopharma, Inc. (NMTR) | 30-Oct-20 | Acquisition (other) | 4,513 | -- | -- | < 1% 615.5K to 620.01K | |
| 14-Sep-20 8:06 AM View: | Sirgo Mark A Director | 9 Meters Biopharma, Inc. (NMTR) | 11-Sep-20 | Market Purchase | 77,000 | $0.68 | $52,360.00 | 17% 461.78K to 538.78K | 68% |
| 14-Sep-20 8:06 AM View: | Sirgo Mark A Director | 9 Meters Biopharma, Inc. (NMTR) | 11-Sep-20 | Market Purchase | 21,485 | $0.65 | $14,003.90 | 4% 538.78K to 560.27K | 75% |
| 14-Sep-20 8:06 AM View: | Sirgo Mark A Director | 9 Meters Biopharma, Inc. (NMTR) | 10-Sep-20 | Market Purchase | 50,000 | $0.60 | $30,000.00 | 12% 411.78K to 461.78K | 92% |
| 24-Aug-20 7:01 AM View: | Temperato John Chief Executive Officer Director | 9 Meters Biopharma, Inc. (NMTR) | 21-Aug-20 | Market Purchase | 70,000 | $0.69 | $48,300.00 | 13% 545.5K to 615.5K | 69% |
| 21-Aug-20 4:20 PM View: | Constantino Michael T. Director | 9 Meters Biopharma, Inc. (NMTR) | 20-Aug-20 | Market Purchase | 34,108 | $0.75 | $25,581.00 | 100% 0 to 34.11K | 55% |
| 17-Aug-20 4:18 PM View: | Temperato John Chief Executive Officer Director | 9 Meters Biopharma, Inc. (NMTR) | 17-Aug-20 | Market Purchase | 35,000 | $0.57 | $19,831.00 | 7% 510.5K to 545.5K | 106% |
| 18-Aug-20 5:19 PM View: | Sirgo Mark A Director | 9 Meters Biopharma, Inc. (NMTR) | 17-Aug-20 | Market Purchase | 100,000 | $0.56 | $56,000.00 | 32% 311.78K to 411.78K | 108% |
| 02-Jul-20 4:28 PM View: | Laumas Sandeep Director | 9 Meters Biopharma, Inc. (NMTR) | 30-Jun-20 | Conversion | 42,400 | -- | -- | 5% 776.37K to 818.77K | |
| 02-Jul-20 4:22 PM View: | Temperato John Chief Executive Officer Director | 9 Meters Biopharma, Inc. (NMTR) | 30-Jun-20 | Conversion | 271,400 | -- | -- | 114% 239.1K to 510.5K | |
| 01-Jul-20 4:39 PM View: | Temperato John Chief Executive Officer Director | 9 Meters Biopharma, Inc. (NMTR) | 30-Jun-20 | Grant | 189,655 | -- | -- | 384% 49.44K to 239.1K | |
| 02-Jul-20 4:25 PM View: | Orbimed Israel Gp Ltd. 10% Owner | 9 Meters Biopharma, Inc. (NMTR) | 30-Jun-20 | Conversion Duplicate | 6,786,500 | -- | -- | 40% 16.99M to 23.77M | |
| 02-Jul-20 4:24 PM View: | Darvish Nissim Director 10% Owner | 9 Meters Biopharma, Inc. (NMTR) | 30-Jun-20 | Conversion | 6,786,500 | -- | -- | 40% 16.99M to 23.77M |
